These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
10. [Cladribine tablets : Oral immunotherapy of relapsing-remitting multiple sclerosis with short yearly treatment periods]. Meuth SG; Ruck T; Aktas O; Hartung HP Nervenarzt; 2018 Aug; 89(8):895-907. PubMed ID: 29523912 [TBL] [Abstract][Full Text] [Related]
11. Position of Cladribine Tablets in the Management of Relapsing-Remitting Multiple Sclerosis: An Expert Narrative Review From the United Arab Emirates. Inshasi JS; Alfahad S; Alsaadi T; Hassan A; Zein T; Mifsud VA; Nouri SI; Shakra M; Shatila AO; Szolics M; Thakre M; Kumar A; Boshra A Neurol Ther; 2021 Dec; 10(2):435-454. PubMed ID: 33891277 [TBL] [Abstract][Full Text] [Related]
12. Cladribine Tablets: A Review in Relapsing MS. Deeks ED CNS Drugs; 2018 Aug; 32(8):785-796. PubMed ID: 30105527 [TBL] [Abstract][Full Text] [Related]
13. Long-term management of multiple sclerosis patients treated with cladribine tablets beyond year 4. Meuth SG; Bayas A; Kallmann B; Linker R; Rieckmann P; Wattjes MP; Mäurer M; Kleinschnitz C Expert Opin Pharmacother; 2022 Sep; 23(13):1503-1510. PubMed ID: 35930260 [TBL] [Abstract][Full Text] [Related]
14. Expert opinion on COVID-19 vaccines and cladribine tablets in MS: A plain language summary. Rieckmann P; Centonze D; Giovannoni G; Hua LH; Oreja-Guevara C; Selchen D; Sørensen PS; Vermersch P; Wiendl H; Salloukh H; Yamout B Neurodegener Dis Manag; 2023 Feb; 13(1):5-13. PubMed ID: 36278394 [TBL] [Abstract][Full Text] [Related]
15. Cost-effectiveness of cladribine tablets, alemtuzumab, and natalizumab in the treatment of relapsing-remitting multiple sclerosis with high disease activity in England. Hettle R; Harty G; Wong SL J Med Econ; 2018 Jul; 21(7):676-686. PubMed ID: 29618273 [TBL] [Abstract][Full Text] [Related]
16. A plain language summary of the impact of vaccines against flu and chickenpox in people with multiple sclerosis treated with cladribine tablets. Schmierer K; Wiendl H; Oreja-Guevara C; Centonze D; Chudecka A; Roy S; Boschert U Neurodegener Dis Manag; 2023 Feb; 13(1):15-21. PubMed ID: 36545912 [TBL] [Abstract][Full Text] [Related]
17. Long-term safety data from the cladribine tablets clinical development program in multiple sclerosis. Leist T; Cook S; Comi G; Montalban X; Giovannoni G; Nolting A; Damian D; Syed S; Galazka A Mult Scler Relat Disord; 2020 Nov; 46():102572. PubMed ID: 33296971 [TBL] [Abstract][Full Text] [Related]
18. A plain language summary on the effectiveness of cladribine tablets compared with other oral treatments for multiple sclerosis: results from the MSBase registry. Spelman T; Ozakbas S; Alroughani R; Terzi M; Hodgkinson S; Laureys G; Kalincik T; Der Walt AV; Yamout B; Lechner-Scott J; Soysal A; Kuhle J; Sanchez-Menoyo JL; Morgado YB; Spitaleri D; Pesch VV; Horakova D; Ampapa R; Patti F; Macdonell R; Al-Asmi A; Gerlach O; Oh J; Altintas A; Tundia N; Wong SL; Butzkueven H; Neurodegener Dis Manag; 2023 Aug; 13(4):215-221. PubMed ID: 37287269 [TBL] [Abstract][Full Text] [Related]
19. Treatment satisfaction, safety, and tolerability of cladribine tablets in patients with highly active relapsing multiple sclerosis: CLARIFY-MS study 6-month interim analysis. Brochet B; Hupperts R; Langdon D; Solari A; Piehl F; Lechner-Scott J; Montalban X; Selmaj K; Valis M; Rejdak K; Havrdova EK; Patti F; Alexandri N; Nolting A; Keller B Mult Scler Relat Disord; 2022 Jan; 57():103385. PubMed ID: 35158476 [TBL] [Abstract][Full Text] [Related]
20. The effect of cladribine tablets in people with more active multiple sclerosis: a plain language summary. Vermersch P; Galazka A; Dangond F; Damian D; Wong SL; Jack D; Harty G Neurodegener Dis Manag; 2022 Dec; 12(6):285-293. PubMed ID: 35920065 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]